Table 1

Patient characteristics and immunogenicity before and after COVID-19

Patient number1234567
Patient characteristics
Age (years)67554445575860
Immunosuppressive therapyRTXRTX, MTXRTX, MTXRTXRTX, Pred, HCQRTX, Pred, AZTRTX, MTX
Months from last RTX to infection8612107711
Further risk factorsAgeBMI=32COPD, BMI=34DM2, HT, BMI=50, OSA, 40 pyHT, BMI=33, 40 pyHT, BMI=30CNI, stroke, hemiparesis
Vaccinations before infection4445344
Last vaccination to infection (days)2935196362530
B cells status
Assessment to infection (days)035196362530
CD19 positive cells (cells/nl)
Immunogenicity before/after infection
Assessment before/after infection (days)0/704/2819/276/228/2025/302/57
Neutralisation capacity (%)13.4/00/012.4/014.2/99.522.9/18.70/00/24.2
IgG against RBD (BAU/ml)†0/12.40/02.3/0139/28451.7/2.00/5.25.2/31.6
IgG against spike protein (BAU/ml)†0/1.60/02.1/44.739.7/19280/3.60/10.859.5/310
T cell response (mIU/ml)n.a./182*n.a./858357/98240*/85*0*/328n.a./n.a.474/930
Date of positive PCR07 December 202114 January 202222 January 202227January 202208 February 202208 February 202213 February 2022
Omicron prevalence at infection (%)<184; Omicron proven9494999999
Symptoms of COVID-19Cough, joint painCough, fever, headache, limb and joint painSore throat, headache, shiveringCough, sore throat, headache, limb pain, fatigueCough, headache, shivering, decreased taste/smellNoneCough, rhinitis, headache, fever
Medication for COVID-19NoneIbuprofene, clarithromycineNoneNoneAcetylsalicylic acidNoneAcetaminophene
WHO rating scale (0 to 10)‡2222212
  • Lower limit of normal for B cells: 0.1 /nl; positive immunogenicity test results in bold letters: >30% for neutralisation capacity, >1 S/CO for IgG which corresponds to >64.2 BAU/ml against RBD and >58.6 BAU/ml against spike protein, >200 mIU/ml=positive and >100 mIU/ml=borderline positive or >135 mIU/ml=positive in case of negative controls <100 mIU/ml for T cell response.

  • *Low response to mitogen positive control.

  • †Converted from semiquantitative S/CO values by conversion formula supplied by manufacturer.

  • ‡According to Marshall et al.6

  • AZT, azathioprine; BMI, body mass index in (kg/m²); CD, cluster of differentiation; CNI, chronic renal insufficiency; COPD, chronic obstructive pulmonary disease; DM2, diabetes mellitus type II; (E)GPA, (eosinophilic) granulomatosis with polyangiitis; HCQ, hydroxychloroquine; HT, hypertension; IgG, immunoglobulin G; IgG4, immunoglobulin-4-associated disease; MPA, microscopic polyangiitis; MTX, methotrexate; n.a., test result not available; OSA, obstructive sleep apnoea; Pred, prednisolone; py, pack years of smoking; RA, rheumatoid arthritis; RBD, receptor binding domain; RTX, rituximab;